New scan could spot childhood cancer faster

NCT ID NCT07111117

Not yet recruiting Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares a new type of PET/CT scan using 18F-MFBG to the current standard scan (123I-MIBG) in 30 children with relapsed or refractory neuroblastoma. The goal is to see if the new scan works as well or better for detecting tumors. If it does, it could offer a quicker and clearer imaging option for these young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-MFBG (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could replace the current standard scan with a faster, more accurate imaging method for children with neuroblastoma.
What could go wrong: This is a small, early-phase study (30 participants) comparing two imaging methods, not testing a treatment. The new scan may not prove superior or practical in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Gustave Roussy

Villejuif, 94805, France
Hôpital Armand Trousseau

Paris, 75012, France
Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.